Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity.
Valencia K, Echepare M, Teijeira Á, Pasquier A, Bértolo C, Sainz C, Tamayo I, Picabea B, Bosco G, Thomas R, Agorreta J, López-Picazo JM, Frigola J, Amat R, Calvo A, Felip E, Melero I, Montuenga LM. Valencia K, et al. Among authors: thomas r. J Exp Med. 2022 Dec 5;219(12):e20220726. doi: 10.1084/jem.20220726. Epub 2022 Sep 28. J Exp Med. 2022. PMID: 36169652 Free PMC article.
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Nogová L, Boellaard R, Kobe C, Hoetjes N, Zander T, Gross SH, Dimitrijevic S, Pellas T, Eschner W, Schmidt K, Bangard C, Hayes W, Thomas RK, Dietlein M, Giaccone G, Hoekstra OS, Lammertsma AA, Wolf J. Nogová L, et al. Among authors: thomas rk. J Nucl Med. 2009 Nov;50(11):1815-9. doi: 10.2967/jnumed.109.065367. Epub 2009 Oct 16. J Nucl Med. 2009. PMID: 19837761 Free article. Clinical Trial.
Blood-based gene expression signatures in non-small cell lung cancer.
Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, Maisel D, Ansén S, Hahn M, Beyer M, Thomas RK, Gathof B, Mauch C, Delank KS, Engel-Riedel W, Wichmann HE, Stoelben E, Schultze JL, Wolf J. Zander T, et al. Clin Cancer Res. 2011 May 15;17(10):3360-7. doi: 10.1158/1078-0432.CCR-10-0533. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558400
Comprehensive genomic profiles of small cell lung cancer.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. George J, et al. Among authors: thomas rk. Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13. Nature. 2015. PMID: 26168399 Free PMC article.
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma.
Valencia K, Sainz C, Bértolo C, de Biurrun G, Agorreta J, Azpilikueta A, Larrayoz M, Bosco G, Zandueta C, Redrado M, Redín E, Exposito F, Serrano D, Echepare M, Ajona D, Melero I, Pio R, Thomas R, Calvo A, Montuenga LM. Valencia K, et al. Among authors: thomas r. Dis Model Mech. 2022 Jan 1;15(1):dmm049137. doi: 10.1242/dmm.049137. Epub 2022 Jan 31. Dis Model Mech. 2022. PMID: 34870316 Free PMC article.
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK. Ji H, et al. Among authors: thomas rk. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. doi: 10.1073/pnas.0510284103. Epub 2006 May 3. Proc Natl Acad Sci U S A. 2006. PMID: 16672372 Free PMC article.
Genomic approaches to lung cancer.
Thomas RK, Weir B, Meyerson M. Thomas RK, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s. doi: 10.1158/1078-0432.CCR-06-0098. Clin Cancer Res. 2006. PMID: 16857815 Review.
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK. Minami Y, et al. Among authors: thomas rk. Oncogene. 2007 Jul 26;26(34):5023-7. doi: 10.1038/sj.onc.1210292. Epub 2007 Feb 19. Oncogene. 2007. PMID: 17311002
8,262 results